Menarini bags Stemline and a rare disease drug in $677M buyout. But will a better offer follow?

John Carroll

Editor & Founder

Italy’s Menarini Group has struck a deal to buy Stemline Therapeutics $STML for $677 million, adding an FDA-approved drug for a rare type of cancer to the portfolio as the therapy angles for a broader OK in Europe.

The drug — which targets CD123 — is Elzonris, which the agency approved for blastic plasmacytoid dendritic cell neoplasm due to capillary leak syndrome on the basis of a tiny positive study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Menarini bags Stemline and a rare disease drug in $677M buyout. But will a better offer follow?

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Katalin Karikó, Drew Weissman win Nobel Prize for mRNA discoveries

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA unveils new rare disease pilot program to increase agency-sponsor communications

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

Data Quality 2.0: The Future of Real-World Evidence

Menar­i­ni bags Stem­line and a rare dis­ease drug in $677M buy­out. But will a bet­ter of­fer fol­low?

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Katal­in Karikó, Drew Weiss­man win No­bel Prize for mR­NA dis­cov­er­ies

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

Menarini bags Stemline and a rare disease drug in $677M buyout. But will a better offer follow?

Katalin Karikó, Drew Weissman win Nobel Prize for mRNA discoveries

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA unveils new rare disease pilot program to increase agency-sponsor communications

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

Data Quality 2.0: The Future of Real-World Evidence